|
Last Updated: Nov 18, 2006 - 12:32:53 PM |
Latest Research
:
Gastroenterology
:
Constipation
:
Lubiprostone
Novel mechanism of action of lubiprostone provides effective and predictable relief in chronic idiopathic constipation
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc., announced today that AMITIZA (lubiprostone), 24-mcg soft-gel capsules, approved by the U.S. Food and Drug Administration (FDA) in January 2006, is now available by prescription in pharmacies across the United States for the treatment of chronic idiopathic constipation in adults. AMITIZA (pronounced ahm-e-TEASE-a) is the first selective chloride channel activator approved for therapeutic use in chronic idiopathic constipation, a condition that affects both men and women and affects patients over the age of 65 more frequently.
Apr 25, 2006 - 9:01:00 PM
<< prev
next >>
|
